Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune ...
Morningstar brands and products Company Portfolio ...
Figure 1: PET scans showing mouse brain and spinal cord dCK activity before (left ... for treating T-cell and B-cell mediated demyelinating diseases such as MS, optic neuritis, and ADEM. The ...
In a mouse model of ocular hypertension ... gene therapy strategies in models of clinically relevant optic nerve diseases, such as glaucoma, optic neuritis, optic neuropathy, and optic atrophy.
Based on the findings, the scientists developed a treatment strategy to block specific inflammatory molecules, which eased MS severity in the mouse model ... treat acute optic neuritis, a common ...
Scientists working to bring back the woolly mammoth have created genetically engineered mice that they say have several ...
The biotech company Colossal Biosciences has long aspired to bring back the extinct woolly mammoth, which roamed the Northern ...
Researchers at the University of Ottawa have made a significant advancement in the field of spinal cord injury research, ...
The team at genetics and biotech firm Colossal Biosciences have imbued rodents with thicker, woolly coats, golden fur and ...
De-extinction company Colossal mixed mammoth and mouse mutations in a single strain to create a shaggy-haired rodent.
Colossal Biosciences, a startup trying to bring the prehistoric mammoth back from extinction, said it has achieved a first ...
Colossal Biosciences has focused on identifying key traits of extinct animals by studying ancient DNA, with a goal to genetically "engineer them into living animals," said CEO Ben Lamm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback